Takeda Pharmaceutical Co (Takeda Pharmaceutical Co) Additional Paid-In Capital : $12,016 Mil(As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Takeda Pharmaceutical Co Additional Paid-In Capital?

Takeda Pharmaceutical Co's quarterly additional paid-in capital declined from Jun. 2023 ($12,323 Mil) to Sep. 2023 ($11,574 Mil) but then increased from Sep. 2023 ($11,574 Mil) to Dec. 2023 ($12,016 Mil).

Takeda Pharmaceutical Co's annual additional paid-in capital declined from Mar. 2021 ($15,533 Mil) to Mar. 2022 ($14,411 Mil) and declined from Mar. 2022 ($14,411 Mil) to Mar. 2023 ($12,934 Mil).

Takeda Pharmaceutical Co Additional Paid-In Capital Historical Data

The historical data trend for Takeda Pharmaceutical Co's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Takeda Pharmaceutical Co Additional Paid-In Capital Chart

Takeda Pharmaceutical Co Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Additional Paid-In Capital

Get a 7-Day Free Trial

14,847.65

15,606.29

15,533.01

14,411.46

12,934.12

Takeda Pharmaceutical Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Additional Paid-In Capital	Get a 7-Day Free Trial															12,689.76	12,934.12	12,322.87	11,573.67	12,016.39

Takeda Pharmaceutical Co Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Takeda Pharmaceutical Co Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Takeda Pharmaceutical Co's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Takeda Pharmaceutical Co (Takeda Pharmaceutical Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Takeda Pharmaceutical Co Ltd (NYSE:TAK) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

TKPHF:USA TAK:Mexico 4502:Japan 4502:Japan 4502:Japan 4502:Japan TKDA:Germany TKD:Germany TKD:Germany TAKP34:Brazil

Address

1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668

Website

https://www.takeda.com

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4 trillion in fiscal 2022. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the U.S., 20% from Japan, 20% from Europe and Canada.